Literature DB >> 20372794

Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation.

John C Cooper1, Mingjian Shi, Fu-Yu Chueh, Srividya Venkitachalam, Chao-Lan Yu.   

Abstract

Lck is an Src family protein tyrosine kinase with predominant T cell expression. Aberrant expression or activation of Lck kinase has been reported in both lymphoid and non-lymphoid malignancies. We showed previously that the signal transduction pathway involving Janus kinase (JAK) and signal transducer and activator of transcription (STAT) is constitutively activated and contributes to Lck-mediated oncogenesis. Under normal physiological conditions, active STAT proteins induce the expression of suppressor of cytokine signaling (SOCS) family proteins to inhibit further JAK/STAT signaling. It is not fully understood whether and how SOCS-mediated negative feedback control is dysregulated in Lck-transformed cells. Here we report that two SOCS family members, SOCS1 and SOCS3, are not expressed in Lck-transformed LSTRA leukemia. While SOCS1 gene is silenced by DNA hypermethylation, loss of SOCS3 expression is through a mechanism independent of epigenetic silencing by DNA methylation. Furthermore, ectopic expression of SOCS1 or SOCS3 leads to reduced cell proliferation and increased apoptosis in Lck-transformed cells. This is consistent with the attenuation of Lck kinase activity by exogenous SOCS1 or SOCS3 expression. Downstream STAT5 activity is also inhibited as shown by reduced STAT5 tyrosine phosphorylation and in vitro DNA binding. All together, our data highlight the importance of silencing multiple SOCS genes in tumorigenesis and support the roles of SOCS1 and SOCS3 as tumor suppressors toward oncogenic Lck kinase.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372794      PMCID: PMC3031791          DOI: 10.3892/ijo_00000603

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  47 in total

1.  The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.

Authors:  S Kamizono; T Hanada; H Yasukawa; S Minoguchi; R Kato; M Minoguchi; K Hattori; S Hatakeyama; M Yada; S Morita; T Kitamura; H Kato; A Yoshimura
Journal:  J Biol Chem       Date:  2001-01-19       Impact factor: 5.157

2.  5-azaC treatment enhances expression of transforming growth factor-beta receptors through down-regulation of Sp3.

Authors:  S Ammanamanchi; M G Brattain
Journal:  J Biol Chem       Date:  2001-07-06       Impact factor: 5.157

3.  Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.

Authors:  J Frantsve; J Schwaller; D W Sternberg; J Kutok; D G Gilliland
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

4.  Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3.

Authors:  A W Roberts; L Robb; S Rakar; L Hartley; L Cluse; N A Nicola; D Metcalf; D J Hilton; W S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

5.  SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma.

Authors:  Oliver Galm; Hirohide Yoshikawa; Manel Esteller; Rainhardt Osieka; James G Herman
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

6.  The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.

Authors:  T Iwamoto; T Senga; Y Naito; S Matsuda; Y Miyake; A Yoshimura; M Hamaguchi
Journal:  Oncogene       Date:  2000-09-28       Impact factor: 9.867

7.  Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas.

Authors:  Hisaki Nagai; Tetsuji Naka; Yoshie Terada; Toshiaki Komazaki; Aya Yabe; Enjing Jin; Oichi Kawanami; Tadamitsu Kishimoto; Noboru Konishi; Mitsutoshi Nakamura; Yasuhito Kobayashi; Mitsuru Emi
Journal:  J Hum Genet       Date:  2003       Impact factor: 3.172

8.  Negative regulation of FAK signaling by SOCS proteins.

Authors:  Enbo Liu; Jean-François Côté; Kristiina Vuori
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

Review 9.  Dysregulation of the protein tyrosine kinase LCK in lymphoproliferative disorders and in other neoplasias.

Authors:  M B Majolini; M Boncristiano; C T Baldari
Journal:  Leuk Lymphoma       Date:  1999-10

10.  Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms.

Authors:  N Fukushima; N Sato; F Sahin; G H Su; R H Hruban; M Goggins
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

View more
  15 in total

1.  Mitochondrial translocation of signal transducer and activator of transcription 5 (STAT5) in leukemic T cells and cytokine-stimulated cells.

Authors:  Fu-Yu Chueh; King-Fu Leong; Chao-Lan Yu
Journal:  Biochem Biophys Res Commun       Date:  2010-10-29       Impact factor: 3.575

2.  Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics.

Authors:  Jennifer M Speth; Loka R Penke; Joseph D Bazzill; Kyung Soo Park; Rafael Gil de Rubio; Daniel J Schneider; Hideyasu Ouchi; James J Moon; Venkateshwar G Keshamouni; Rachel L Zemans; Vibha N Lama; Douglas A Arenberg; Marc Peters-Golden
Journal:  JCI Insight       Date:  2019-10-17

3.  Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients.

Authors:  Guanghua Li; Jianbo Xu; Zhao Wang; Yujie Yuan; Yin Li; Shirong Cai; Yulong He
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-28       Impact factor: 4.553

4.  Novel role for p56/Lck in regulation of endothelial cell survival and angiogenesis.

Authors:  Venkaiah Betapudi; Meenal Shukla; Ravi Alluri; Sergei Merkulov; Keith R McCrae
Journal:  FASEB J       Date:  2016-07-11       Impact factor: 5.191

5.  Frequent SOCS3 and 3OST2 promoter methylation and their epigenetic regulation in endometrial carcinoma.

Authors:  Haiyan Chen; Cuijuan Zhang; Yan Sheng; Shuzhe Yao; Zhiyan Liu; Cheng Zhang; Tingguo Zhang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

6.  Suppressor of cytokine signaling 1 interacts with oncogenic lymphocyte-specific protein tyrosine kinase.

Authors:  Srividya Venkitachalam; Fu-Yu Chueh; King-Fu Leong; Samantha Pabich; Chao-Lan Yu
Journal:  Oncol Rep       Date:  2011-01-13       Impact factor: 3.906

7.  Engagement of T-cell antigen receptor and CD4/CD8 co-receptors induces prolonged STAT activation through autocrine/paracrine stimulation in human primary T cells.

Authors:  Fu-Yu Chueh; Chao-Lan Yu
Journal:  Biochem Biophys Res Commun       Date:  2012-08-23       Impact factor: 3.575

8.  Chimeric Peptidomimetics of SOCS 3 Able to Interact with JAK2 as Anti-inflammatory Compounds.

Authors:  Sara La Manna; Laura Lopez-Sanz; Flavia Anna Mercurio; Sara Fortuna; Marilisa Leone; Carmen Gomez-Guerrero; Daniela Marasco
Journal:  ACS Med Chem Lett       Date:  2020-03-19       Impact factor: 4.345

9.  Nuclear localization of pyruvate dehydrogenase complex-E2 (PDC-E2), a mitochondrial enzyme, and its role in signal transducer and activator of transcription 5 (STAT5)-dependent gene transcription.

Authors:  Fu-Yu Chueh; King-Fu Leong; Robert J Cronk; Srividya Venkitachalam; Samantha Pabich; Chao-Lan Yu
Journal:  Cell Signal       Date:  2011-03-17       Impact factor: 4.315

10.  Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression.

Authors:  Xin Zhang; Junling Liu; Dan Zang; Shu Wu; Aibin Liu; Jinrong Zhu; Geyan Wu; Jun Li; Lili Jiang
Journal:  Oncotarget       Date:  2015-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.